Genetic Pancreatic Cancer Test

The Genetic Pancreatic Cancer Panel provides a comprehensive genetic screening to assess your inherited risk of pancreatic cancer, a rare but highly aggressive cancer. This easy, at-home saliva test empowers you to understand your health and take proactive steps. Suitable for individuals aged 18 and over, particularly those with a family history of pancreatic cancer, this test offers valuable insights into your genetic risk, helping you stay informed and vigilant.

Pancreatic cancer originates in the pancreas, a vital organ located behind the stomach that plays a crucial role in digestion and blood sugar regulation. Although pancreatic cancer is less common than other cancers, it is one of the deadliest, often going undetected until advanced stages. In the UK, around 10,000 people are diagnosed with pancreatic cancer annually, while globally, it affects over 460,000 people each year. Both men and women are equally affected by this type of cancer, and early detection is critical for improving outcomes.

Pancreatic cancer can be challenging to detect early, as it often presents subtle symptoms or none at all in the initial stages. Common symptoms include:

This panel screens for genetic mutations associated with an increased risk of pancreatic cancer, helping you understand your potential inherited risks.

BRCA1 and BRCA2: Known primarily for their role in breast and ovarian cancers, these mutations also increase the risk of pancreatic cancer.

PALB2: Mutations in this gene are associated with a heightened risk of developing pancreatic cancer, particularly among those with a family history.

ATM: This gene is involved in DNA repair, and mutations can increase pancreatic cancer risk.

CDKN2A: Mutations in CDKN2A elevate the risk of several cancers, including pancreatic cancer, especially in families with a history of this disease.

Our Genetic Pancreatic Cancer Panel uses Genome Nanopore Sequencing (GNS) technology, an advanced technique for detecting key genetic mutations associated with pancreatic cancer. This £449 panel provides essential insights, enabling you to take preventive steps and discuss options with your healthcare provider.

Convenient at-home saliva test: Perform the test comfortably at home, with no need for clinic visits.

Fast, secure results: Receive a comprehensive report within 15 days, sent to you via secure email.

Personalised insights: This panel focuses on identifying mutations specifically linked to pancreatic cancer, empowering you with clear information.

Non-invasive: A simple saliva test is all that’s required, making the process straightforward and stress-free.

Order Online: Securely place your order on our website.

Collect Your Saliva Sample: Follow the easy-to-understand instructions provided in your kit.

Return Your Sample: Return your saliva swab back to our lab for analysis using a temperature-controlled courier for secure, accurate results.

Receive Your Results: Within 15 days, a detailed report outlining any genetic mutations and associated risks will be emailed to you securely.

The Genetic Pancreatic Cancer Panel is suitable for anyone aged 18 and over who wants to understand their genetic risk for pancreatic cancer. This test is especially beneficial for individuals with a family history of pancreatic cancer, those with known genetic mutations such as BRCA1 or BRCA2, or individuals of Ashkenazi Jewish descent, who have a higher prevalence of these mutations. Early knowledge of genetic risk allows for proactive measures, such as enhanced screenings or lifestyle adjustments.

Genetic testing provides invaluable insights, particularly for individuals at an increased risk of pancreatic cancer. The Genetic Pancreatic Cancer Panel offers essential information to guide your healthcare decisions and support early detection efforts. If your results indicate an elevated risk, we recommend consulting with your healthcare provider to explore preventive options.

Order Your Genetic Pancreatic Cancer Panel for £449 and take the first step toward proactive health management today.